Aberrant huntingtin interacting protein 1 in lymphoid malignancies

Sarah V. Bradley, Mitchell R. Smith, Teresa S. Hyun, Peter C. Lucas, Lina Li, Danielle Antonuk, Indira Joshi, Fang Jin, Theodora S. Ross

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Huntingtin interacting protein 1 (HIP1) is an inositol lipid, clathrin, and actin binding protein that is overexpressed in a variety of epithelial malignancies. Here, we report for the first time that HIP1 is elevated in non-Hodgkin's and Hodgkin's lymphomas and that patients with lymphoid malignancies frequently had anti-HIP1 antibodies in their serum. Moreover, p53-deficient mice with B-cell lymphomas were 13 times more likely to have anti-HIP1 antibodies in their serum than control mice. Furthermore, transgenic overexpression of HIP1 was associated with the development of lymphoid neoplasms. The HIP1 protein was induced by activation of the nuclear factor-KB pathway, which is frequently activated in lymphoid malignancies. These data identify HIP1 as a new marker of lymphoid malignancies that contributes to the transformation of lymphoid cells in vivo.

Original languageEnglish (US)
Pages (from-to)8923-8931
Number of pages9
JournalCancer research
Volume67
Issue number18
DOIs
StatePublished - Sep 15 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Aberrant huntingtin interacting protein 1 in lymphoid malignancies'. Together they form a unique fingerprint.

Cite this